Johnson & Johnson

News

J&J bags first FDA approval for a GPRC5D drug

Johnson & Johnson has become the first drugmaker to get FDA approval for a drug targeting GPRC5D, getting the nod for its bispecific antibody Talvey for a group of pat

News

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

Johnson & Johnson has bolstered its oncology pipeline by licensing a drug from Nanobiotix designed to enhance the effectiveness of radiotherapy for solid tumours.

News

J&J files Carvykti for earlier use in multiple myeloma

As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo

News

AZ posts first-line combo data for lung cancer drug Tagrisso

AstraZeneca’s top-selling drug Tagrisso is already widely used on its own as a first-line treatment for EGFR-mutated lung cancer, but new data suggests there can be benefi

News

J&J sets top price for consumer health unit Kenvue’s IPO

Johnson & Johnson’s consumer health unit Kenvue looks set to raise $3.8 billion in an upsized initial public offering (IPO), valuing the business at around $41 billion

News

J&J builds in CAR-T with $245m Cellular Biomedicine deal

Johnson & Johnson’s appetite for building a new generation of CAR-T therapies for cancer shows no sign of being sated – its Janssen Biotech unit has just paid $245 mil

J&J bags first FDA approval for a GPRC5D drug

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

J&J files Carvykti for earlier use in multiple myeloma

AZ posts first-line combo data for lung cancer drug Tagrisso

J&J sets top price for consumer health unit Kenvue’s IPO

J&J builds in CAR-T with $245m Cellular Biomedicine deal

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Johnson & Johnson

Editor's Picks